2007
DOI: 10.1016/j.bmcl.2007.04.088
|View full text |Cite
|
Sign up to set email alerts
|

The discovery of 2-amino-3,5-diarylbenzamide inhibitors of IKK-α and IKK-β kinases

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
37
0

Year Published

2007
2007
2019
2019

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 59 publications
(38 citation statements)
references
References 12 publications
1
37
0
Order By: Relevance
“…Interestingly, IKK Inhibitor XII, a selective inhibitor of NF- к B signalling that functions by decreasing NF- к B phosphorylation and thus reducing the probability of translocation of the NF- к B into the nucleus, also prevented SAPK/JNK activation in LPS-treated cells (Figure 2). These results coincide with findings demonstrating that SAPK/JNK signalling is regulated by the NF- к B pathway [20, 21]. Indeed, it is generally suggested that NF- к B activation plays a critical role in LPS-induced responses and that the suppression of NF- к B pathway activity prevents its ability to activate the transcription of a wide variety of genes encoding immunologically relevant proteins.…”
Section: Discussionsupporting
confidence: 89%
“…Interestingly, IKK Inhibitor XII, a selective inhibitor of NF- к B signalling that functions by decreasing NF- к B phosphorylation and thus reducing the probability of translocation of the NF- к B into the nucleus, also prevented SAPK/JNK activation in LPS-treated cells (Figure 2). These results coincide with findings demonstrating that SAPK/JNK signalling is regulated by the NF- к B pathway [20, 21]. Indeed, it is generally suggested that NF- к B activation plays a critical role in LPS-induced responses and that the suppression of NF- к B pathway activity prevents its ability to activate the transcription of a wide variety of genes encoding immunologically relevant proteins.…”
Section: Discussionsupporting
confidence: 89%
“…41,42 The phase I clinical trial of topical formulation of IMD-0354 for treatment of atopic dermatitis has been successfully completed. Other synthetic IKK inhibitors, including S1627, 43 2-benzamido-pyrimidines, 44 2-amino-3,5-diarylbenzamides, 45,46 6-aryl-7-alkoxyisoquinolines, 47 4-phenyl-7-azaindoles, 48 PHA-408 49,50 and PF-184, 50 have been reported.…”
Section: Synthetic Ikk Inhibitorsmentioning
confidence: 99%
“…According to previous studies [12,14,38,39] those models representing portions of the enzyme far from the active site (the ATP binding pocket comprised between residues 44, 90, and 145) were discarded. The resulting models were further discriminated by examining the percentage of identity with the template sequence and the provided ModelScore value.…”
Section: Resultsmentioning
confidence: 99%
“…SAR modifications on this compound allowed the design of 2-(aminocarbonyl)amino-5-acetylenyl-3-thiophenecarboxamides (2) [13], a novel class of inhibitors with an improved activity and selectivity. More recently [14], the IKK-␤ inhibitors providing a 2-amino-3,5-diarylbenzamide scaffold (3) were discovered starting from structure-activity studies on a series of IKK-inhibitors, part of an PMA-inducible IkB kinase complex with a structural homology to IKK-␣ of 30% [15].…”
Section: Introductionmentioning
confidence: 99%